UCAR-T cells

BIOLOGICAL3 trials

Sponsors

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, The Affiliated Hospital of Xuzhou Medical University

Conditions

B-ALLB-cell Acute Lymphoblastic LeukemiaInflammatory MyopathySystemic Lupus ErythematosusSystemic Sclerosis

Early Phase 1

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

WithdrawnNCT07410377

The Affiliated Hospital of Xuzhou Medical UniversityInflammatory Myopathy, Systemic Lupus Erythematosus

Start: 2026-03-01End: 2028-09-01Updated: 2026-05-28

Phase 1

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaB-ALL, B-cell Acute Lymphoblastic Leukemia

Start: 2022-12-05End: 2025-12-31Target: 30Updated: 2022-12-08

Unknown Phase

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Active, not recruitingNCT07155369

The Affiliated Hospital of Xuzhou Medical UniversitySystemic Lupus Erythematosus, Systemic Sclerosis

Start: 2025-03-18End: 2028-09-30Target: 18Updated: 2025-09-04